HOME >> BIOLOGY >> NEWS
Gene responsible for common hearing loss identified for first time

A gene responsible for the single most common cause of hearing loss among white adults, otosclerosis, has been identified for the first time, a scientist told the annual conference of the European Society of Human Genetics in Nice, France. Ms Melissa Thys, from the Department of Medical Genetics, University of Antwerp, Belgium, said that this finding may be a step towards new treatments for otosclerosis, which affects approximately 1 in 250 people.

Otosclerosis is a multifactorial disease, caused by an interaction of genetic and environmental factors. The outcome is a progressive hearing loss as the growing bone in the middle ear interrupts the sound waves passing to the inner ear. While the causative factors remain unknown, now one of the genetic components has been identified, Ms Thys told the conference. The gene in which the variant is located points to a pathway that contributes to the disease. This may be a lead for better forms of treatment in the future; currently the best option is an operation. However, there is often an additional component of hearing loss which cant be restored by surgery. As the gene involved is a growth factor, and the disease manifests itself by the abnormal growth of bone in the middle ear, it may have a large potential for therapy, she said. Improved understanding may also lead to prevention strategies.

Ms Thys and her team decided to study a gene called TGBF1 which they already knew had non-genetic indications of involvement in otosclerosis: it plays a role during embryonic development of the ear and is expressed in otosclerotic bone. They used SNP (single nucleotide polymorphism) analysis, or looking at DNA sequence variations occurring in a single nucleotide, A, T, C or G, to study a large patient and control population from Belgium and The Netherlands. They found significant results for an amino acid changing SNP inTGBF1, and that this remained significant after correcting for multiple testing. Analysis
'"/>

Contact: Mary Rice
mary@mrcommunication.org
European Society of Human Genetics
16-Jun-2007


Page: 1 2

Related biology news :

1. Researchers discover gene responsible for Restless Legs Syndrome
2. Researchers identify fifth gene responsible for Joubert syndrome
3. A researcher identifies the parasites responsible for Chagas and Leishmaniasis epidemics
4. Scientists sequence genome of parasite responsible for common sexually transmitted infection
5. One gene 90 percent responsible for making common parasite dangerous
6. Study uncovers mutation responsible for Noonan Syndrome
7. Researchers discover new gene responsible for brittle bone disease
8. Researchers identify taste receptor responsible for caffeine detection
9. Expression of Blimp1 gene leads to the discovery of cells responsible for skins sebaceous gland
10. A single sugar found responsible for an antibodys ability to treat inflammation
11. Gene mutations responsible for Rett syndrome in females present sporadically in males

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene responsible for common hearing loss identified for first time

(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
(Date:3/19/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... week on Washington DC,s Fox 5 ... "The Next Great Thing", host Laura Evans calls ... ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
(Date:4/16/2015)... MOSCOW , April 16, 2015 /PRNewswire/ ... (ChemRar), the Russian pharmaceutical investment and R&D ... announced collaboration for research, development and commercialization ... with the intention to stimulate ... industry.      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., a ... therapeutic antibodies, today announced the advancement of ... into IND-enabling studies. The Company,s anti-IL-36R therapeutic ... for generalized pustular psoriasis (GPP), an orphan ... need. ANB019 is wholly owned within AnaptysBio,s proprietary ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... LAUSANNE , Switzerland ... Debiopharm International SA (Debiopharm), part of Debiopharm Group ™ ... prescription drugs that target unmet medical needs ... that preclinical data on the investigational compounds ... inhibitor) will be presented at the 2015 ...
Breaking Biology Technology:Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
Cached News: